Abstract
Background After completion of TB treatment patients may remain at-risk of complications and mortality. We determined the survival and predictors of all-cause mortality after completing TB treatment among ART experienced patients.
Methods This was a retrospective cohort analysis of all ART experienced patients who completed TB treatment at a specialist HIV clinic in Uganda, between 2009 and 2014. The patients were followed for five years after TB treatment. We determined mortality rate, probability of death, and predictors of all-cause mortality after TB treatment using Poisson methods, Kaplan-Meier methods, and Cox proportional hazard models, respectively.
Results A total 1,287 patients completed TB treatment between 2009 and 2014, of which 1,111 were included in the analysis. At TB treatment completion, the median age was 36 years (IQR: 31-42), 563 (50.7%) were males, and median CD4 count was 235 cells/mL (IQR: 139-366). The person time at risk was 4410.60 person-years. The all-cause mortality rate was 15.42 per 1000 person-years (95% CI: 12.14-19.59). The probability of death at five years was 6.9% (95%CI: 5.5%-8.8%). In the multivariable analysis, CD4 count<200 cells/mL was a predictor of all-cause mortality (aHR=1.81, 95%CI:1.06 - 3.11, p=0.03) alongside TB history (aHR=2.12, 95%CI: 1.16 - 3.85, p=0.01).
Conclusion Survival post TB treatment in ART experienced PLHIV is reasonably good and most deaths occur within two years of TB treatment completion. Patients with low CD4 and those with history of treatment have an increased risk of mortality which underscores the need for TB prophylaxis, detailed assessment, and close monitoring after TB treatment.
What is already known on this topic Tuberculosis is the leading cause of death in PLHIV and patients who complete treatment remain at risk of mortality. However, it is not clear what the mortality rate is, when it occurs, and what factors are associated with mortality in exclusively ART experienced patients.
What this study adds Most deaths occur within two years after treatment completion decreasing drastically by year five. Patients with low CD4 count after TB treatment have an 81% increased risk of death and those with a history of TB have a 200% increased risk of mortality.
How this study might affect research, practice or policy The study provides a detailed understanding of post-TB survival in ART experienced PLHIV and underscores the need for programs and clinics to re-define TB treatment success and consider the use of enhanced prophylaxis after TB treatment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional review board (IRB) of Makerere University College of Health Sciences gave ethical approval for this analysis (approval number: 120-2009), and the IRB waived the need for informed consent to analyse this data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos